PriceTargets.com logo

NASDAQ:CBIO - Catalyst Biosciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.00
  • Forecasted Upside: 482.01 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.89 As of 08/16/2022 10:36 AM ET
▼ -0.04 (-2.07%)

This chart shows the closing price for CBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Catalyst Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBIO

Analyst Price Target is $11.00
▲ +482.01% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Catalyst Biosciences in the last 3 months. The average price target is $11.00, with a high forecast of $18.00 and a low forecast of $4.00. The average price target represents a 482.01% upside from the last price of $1.89.

This chart shows the closing price for CBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Catalyst Biosciences. This rating has held steady since June 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/17/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2021JonestradingDowngradeBuy ➝ HoldHigh
11/12/2021Piper SandlerLower Price TargetOverweight$16.00 ➝ $4.00High
11/12/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
9/10/2021JonestradingReiterated RatingBuy$18.00Medium
8/9/2021JonestradingInitiated CoverageBuy$18.00Low
8/6/2021Raymond JamesLower Price TargetOutperform$19.00 ➝ $18.00Medium
7/20/2021Raymond JamesSet Price TargetBuy$4.31High
7/1/2021Chardan CapitalReiterated RatingBuyHigh
4/29/2021Raymond JamesBoost Price TargetOutperform$18.00 ➝ $19.00Low
3/4/2021Raymond JamesSet Price TargetOutperform$18.00High
2/10/2021Piper SandlerInitiated CoverageOverweight$15.00Low
2/4/2021Raymond JamesLower Price TargetOutperform$20.00 ➝ $18.00High
12/15/2020Raymond JamesSet Price TargetOutperform$20.00Medium
12/3/2020Raymond JamesReiterated RatingOutperform$20.00High
11/5/2020Lifesci CapitalReiterated RatingOutperformHigh
11/5/2020Raymond JamesReiterated RatingBuy$20.00High
8/7/2020Raymond JamesSet Price TargetOutperform$20.00N/A
8/6/2020Ci CapitalReiterated RatingBuy$18.00Low
7/22/2020Ci CapitalReiterated RatingBuy$19.00Low
7/14/2020Raymond JamesSet Price TargetOutperform$20.00Low
6/17/2020Raymond JamesSet Price TargetOutperform$20.00High
6/11/2020Raymond JamesSet Price TargetOutperform$20.00Low
5/21/2020Raymond JamesInitiated CoverageOutperform$20.00High
12/19/2019Chardan CapitalReiterated RatingBuy$25.00High
11/10/2019Chardan CapitalReiterated RatingBuy$25.00Low
8/25/2019Chardan CapitalSet Price TargetBuy$25.00High
1/4/2019CIBCInitiated CoverageOutperform ➝ Outperform$24.00High
1/4/2019OppenheimerInitiated CoverageOutperform$24.00 ➝ $24.00High
12/20/2018Chardan CapitalReiterated RatingBuy$35.00High
6/21/2018B. RileyDowngradeBuy ➝ Neutral$44.00 ➝ $12.50Low
6/19/2018Chardan CapitalReiterated RatingBuy$35.00Low
5/14/2018B. RileySet Price TargetBuy$44.00High
2/9/2018B. RileySet Price TargetBuy ➝ Buy$19.00 ➝ $49.00High
2/9/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$10.00 ➝ $75.00High
2/1/2018B. RileyReiterated RatingBuy$19.00High
12/18/2017B. RileySet Price TargetBuy$19.00Low
12/8/2017B. RileyInitiated CoverageBuy$19.00High
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2022

Current Sentiment

  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Catalyst Biosciences logo
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.89
Low: $1.89
High: $1.89

50 Day Range

MA: $1.68
Low: $1.33
High: $1.93

52 Week Range

Now: $1.89
Low: $0.35
High: $5.20

Volume

10 shs

Average Volume

335,769 shs

Market Capitalization

$59.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Catalyst Biosciences?

The following Wall Street research analysts have issued research reports on Catalyst Biosciences in the last year: Jonestrading, Piper Sandler, and Raymond James.
View the latest analyst ratings for CBIO.

What is the current price target for Catalyst Biosciences?

2 Wall Street analysts have set twelve-month price targets for Catalyst Biosciences in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 469.9%. Jonestrading has the highest price target set, predicting CBIO will reach $18.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.00 for Catalyst Biosciences in the next year.
View the latest price targets for CBIO.

What is the current consensus analyst rating for Catalyst Biosciences?

Catalyst Biosciences currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CBIO, but not buy more shares or sell existing shares.
View the latest ratings for CBIO.

What other companies compete with Catalyst Biosciences?

Other companies that are similar to Catalyst Biosciences include Merrimack Pharmaceuticals, Molecular Templates, Regulus Therapeutics, Infinity Pharmaceuticals and Bolt Biotherapeutics. Learn More about companies similar to Catalyst Biosciences.

How do I contact Catalyst Biosciences' investor relations team?

Catalyst Biosciences' physical mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 871-0761 and its investor relations email address is [email protected] The official website for Catalyst Biosciences is www.catalystbiosciences.com. Learn More about contacing Catalyst Biosciences investor relations.